CDC and FDA expedite the availability of additional doses of new RSV immunization for infants

Nov. 17, 2023
CDC and FDA will continue to be in close contact with manufacturers to ensure the availability of additional doses through end of this year and for early 2024 to meet the demand.

The Centers for Disease Control and Prevention (CDC) announced the release of more than 77,000 additional doses of Beyfortus (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease. 

These additional doses will be distributed immediately to physicians and hospitals through the Vaccines for Children Program and commercial channels – improving the availability of nirsevimab-alip for parents seeking to protect their eligible children, particularly those at highest risk of severe illness.

CDC release